Pharos Anounces New Clincial Trials For Wireless Breast Tumor Marker Technology

CONCORD, Mass. - Oct. 30, 2013 - PRLog -- Pharos Devices announced today new multi-site clinical studies for its next generation wireless breast cancer tumor marker technology. Pharos develops innovative sensing and localization products that make medical procedures more efficient, effective and mobile.

The TagFinder product, is a handheld radio frequency reader that can detect markers embedded in the body. Its first application is detecting markers placed around breast lesions for surgical removal. This product eliminates the need for a day-of-surgery procedure that currently causes a significant number of operating room delays and cancellations. The TagFinder is in development with commercial release scheduled for 2014.

The trials are taking place at leading university breast cancer centers in the United States. The technology has already been used in over thirty patients. “More effective breast cancer surgical procedures is an area of pressing clinical need, and our decision to expand the TagFinder program was based on promising early clinical evidence in breast cancer patients”, says Chris Adams, Chairman and co-founder.

The Pharos TagFinder product target customers are the breast surgeons and radiologists in approximately 5,000 breast centers world-wide who perform more than a million breast lesion excisions annually.

About Pharos Devices

Pharos Devices is an early stage company that develops and markets innovative sensing and localization products that make medical procedures more efficient, effective and mobile. www.pharosdevices.com